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Introduction
Pioglitazone, an agonist of peroxisome proliferator- 
activated receptor γ (PPAR γ), has been shown to improve 
glycemic levels in patients with type 2 diabetes mellitus 
(T2DM) [1]. It belongs to the thiazolidinedione class 
and has been used for treating T2DM since its approval 
by the US Food and Drug Administration (FDA) in 
1999. Additionally, evidence suggests that pioglitazone 
offers a benefit in reducing the risk of cardiovascular 
outcomes (e.g., stroke) as well as levels of various 
inflammatory factors [2, 3]. However, in 2005, an 
increased risk of bladder cancer among patients treated 
with pioglitazone versus placebo was observed in the 
prospective pioglitazone clinical trial in macrovascular 
events (PROactive) [4]. Subsequent observational studies 
seemed to support this finding and indicated a dose- 
dependent relationship [5, 6]. Given the increased risk 
of bladder cancer, Germany, France, and then India 
suspended the marketing of pioglitazone, and the US 
FDA added a warning against use by patients with active 
bladder cancer [7].
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Abstract
Current evidence about the association between pioglitazone and bladder cancer 
risk remains conflict. We aimed to assess the risk of bladder cancer associated 
with the use of pioglitazone and identify modifiers that affect the results. We 
systematically searched PubMed, Embase, and Cochrane Central Register of 
Controlled Trials from inception to 25 August 2016 for randomized controlled 
trials (RCTs) and observational studies that evaluated the association between 
pioglitazone and bladder cancer risk. Conventional and cumulative meta- analyses 
were used to calculate the odds ratio (OR) with 95% confidence interval (CI). 
A restricted spline regression analysis was used to examine the dose–response 
relationship with a generalized least- squares trend test. We included two RCTs 
involving 9114 patients and 20 observational studies (n = 4,846,088 individuals). 
An increased risk of bladder cancer in patients treated with pioglitazone versus 
placebo was noted from RCTs (OR, 1.84; 95%CI, 0.99 to 3.42). In observational 
studies, the increased risk of bladder cancer was slight but significant among 
ever- users of pioglitazone versus never- users (OR, 1.13; 95%CI, 1.03 to 1.25), 
which appeared to be both time- (P = 0.003) and dose- dependent (P = 0.05). 
In addition, we observed the association differed by region of studies (Europe, 
United States, or Asia) or source of funding (sponsored by industry or not). 
Current evidence suggests that pioglitazone may increase the risk of bladder 
cancer, possibly in a dose- and time- dependent manner. Patients with long- term 
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Subsequently, a number of observational studies were 
conducted to explore the association between pioglitazone 
use and risk of bladder cancer, but reached inconsistent 
conclusions. In 2015, one ten- year interim analysis in a 
large observational study of the Kaiser Permanente 
Northern California (KPNC) database, which was required 
by US FDA, found that use of pioglitazone was not sig-
nificantly associated with increased risk of bladder cancer 
in the United States [8]. The null findings were consistent 
with those of another large retrospective cohort study 
from four databases in Europe [9], and recently, the 10- 
year follow- up of the PROactive trial also detected no 
increased risk [10]. However, one population- based cohort 
study reported a positive association [11]. On 12 December 
2016, US FDA provided a narrative review of four studies 
[4, 8, 10, 11] and made a statement of an increased risk 
of bladder cancer associated with use of pioglitazone [12].
Because of the ongoing safety concerns, there is a criti-
cal need for a rigorous assessment of the bladder safety 
of pioglitazone. Furthermore, several effect modifiers (e.g., 
gender, region of study, and cumulative dose or duration 
of pioglitazone) may contribute to the risk of bladder 
cancer; however, they have not been fully explored in 
previous meta- analyses [13–18]. In this systematic review 
and meta- analysis, we therefore conducted a cumulative 
meta- analysis of all available evidence from observational 
studies to describe the development of the evidence over 
time, as well as a dose- response meta- analysis to assess 
this association. Additionally, we assess the potential fac-
tors using a meta- regression analysis.
Methods
Search strategy and inclusion criteria
Following the PRISMA guidelines [19], we systematically 
searched PubMed, Embase, and Cochrane Central Register 
of Controlled Trials (CENTRAL) to identify randomized 
controlled trials or observational studies published up to 
25 August 2016 that evaluated the association between 
exposure to pioglitazone and risk of bladder cancer. The 
combined terms—”((thiazolidinedione* or glitazone* or 
pioglitazone or rivoglitazone or rosiglitazone or troglitazone) 
and (neoplasms OR cancer))”—were used with a restriction 
in “human” only. A manual search was performed on the 
reference lists of included studies and systematic reviews.
We included randomized controlled trials (RCTs) fulfill-
ing the following inclusion criteria: (1) parallel- group design; 
(2) pioglitazone as the intervention versus a control treat-
ment including nonthiazolidinedione therapy, nonpioglita-
zone therapy, or placebo; and (3) reporting the events of 
bladder cancer. In addition, we also considered observational 
studies (cohort or case- control studies) reporting on the 
risk of bladder cancer associated with use of pioglitazone 
versus never use of pioglitazone/thiazolidinedione. We 
excluded the conference abstracts as well as the articles 
without reporting the bladder cancer outcome.
Study selection and data extraction
Two reviewers (HT and WS) independently checked titles 
and abstracts to exclude articles that clearly did not fulfill 
the inclusion criteria. Any potentially eligible studies were 
further assessed by retrieving full texts. A standardized 
data extraction form was used to collect the following 
information: study design, drug use, region of study, 
characteristics of participants, selection criteria, exposure 
definition, controlled covariates, funding, and data on 
bladder cancer risk (e.g., adjusted hazard ratio (HR), 
adjusted risk ratio (RR), and adjusted odds ratio (OR)).
Risk of bias
Two reviewers (HT and WS) independently used the 
Cochrane risk- of- bias tool and the Newcastle- Ottawa quality 
assessment scale (NOS) to assess the quality of RCTs and 
observational studies, respectively [20, 21]. For RCTs, the 
risk of bias was assessed as low, high, or unclear for each 
of the following items: random sequence generation (selec-
tion bias), allocation concealment (selection bias), blinding 
(performance bias or detection bias), incomplete outcome 
data (attrition bias), and selective reporting (reporting bias) 
[20]. For observational studies, a maximum of nine stars 
were allocated to the domains of selection, comparability, 
and outcome/exposure, with higher scores indicating better 
quality [21]. Any disagreements were resolved by consensus 
or referral to a third reviewer (JH).
Statistical analysis
We pooled the data for RCTs and observational studies 
separately. For RCTs, a Peto’s OR with 95% confidence 
interval (CI) was used to pool the outcome data due to 
rare events of bladder cancer [22]. For observational stud-
ies, OR with 95%CI was pooled using conventional and 
cumulative random- effects meta- analyses. Although the 
effect measures are different between cohort studies (HR 
or RR) and case–control studies (OR), they are relative 
measures and are considered to be similar when the event 
rate is low (<5%) [23]. Statistical heterogeneity was quan-
tified using the I2 statistic, with I2 of <25%, ≥25% and 
<75%, and ≥75% indicating low, medium, and high het-
erogeneity, respectively [24]. A meta- regression analysis 
was carried out to investigate whether the estimates were 
affected by the following factors: cumulative dose (≤10.5 g 
vs. 10.5–28 g vs. >28 g; or ≤14 g vs. 14–40 g vs. >40 g), 
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cumulative duration (≤1 year vs. 1–2 years vs. >2 years; 
or ≤1.5 year vs. 1.5–4 years vs. >4 years), region of study 
(Europe vs. United States vs. Asia), type of comparison 
group (never use of pioglitazone versus never use of thia-
zolidinedione vs. specified drug), gender (women vs. men), 
smoking adjusted (adjusted for smoking vs. no adjusted 
for smoking), and source of funding (industry vs. other). 
A sensitivity analysis omitting each study successively was 
performed to investigate the influence of each individual 
study on the overall meta- analysis summary estimates. For 
the studies with possible overlapping patients, additional 
sensitivity analysis was also performed by including the 
most recent study only. In addition, publication bias for 
risk of bladder cancer was assessed using Begg’s and Egger’s 
tests, as well as visual inspection of the funnel plots [25].
We tested possible dose and time responses of risk of 
bladder cancer using restricted cubic splines random- effects 
meta- analysis, with three knots at the 10th, 50th, and 
90th percentiles of the distribution. We also used the 
method described by Greenland and Longnecker [26] and 
Orsini et al. [27] for the dose- response analysis to com-
pute the trend from the correlated ORs and 95% CIs 
across categories of cumulative dose and cumulative dura-
tion. The numbers of case and control subjects or person- 
years by category were extracted if available. The median 
or mean cumulative dose or cumulative duration in each 
category was assigned to the corresponding OR. If median 
or mean values were unavailable, we used the categorical 
midpoint. For open- ended categories, 0.5 times of the 
higher boundary (for the lowest category) or 1.5 times 
of the lower boundary (for the highest category) were 
set to obtain the midpoints [28, 29].
All statistical analyses were performed with STATA 
(Version 14; Stata Corp., College Station, TX). A two- 
tailed P < 0.05 was considered statistically significant.
Results
Study selection
Of 5224 citations identified from electronic databases, 128 
studies were potentially eligible after initial title and abstract 
evaluations. After further assessment through retrieving 
full texts, 22 studies proved eligible, including two RCTs 
and 20 observational studies (12 cohort studies and eight 
case–control studies). No additional studies were identified 
in the manual search. The process of study selection with 
reasons for exclusion is presented in Figure 1.
Evidence from RCTs
Two large randomized, placebo- controlled trials reporting 
the outcomes of bladder cancer were eligible and included 
[2, 4]. One was performed in patients without diabetes, 
but had insulin resistance and a recent history of ischemic 
stroke or transient ischemic attack [2]. The other trial 
included T2DM patients who showed evidence of mac-
rovascular disease [4]. The mean length of follow- up was 
4.8 years and 2.9 years, respectively. The risk of bias in 
both trials was low, and both groups in each trial were 
generally balanced with respect to demographic and clini-
cal characteristics. The characteristics and risk of bias of 
included RCTs are presented in Table S1 and Figure S1, 
respectively.
These two trials reported a total of 40 cases of bladder 
cancer among 9114 patients (raw event rate 0.4%), with 
26 cases among 4544 patients (raw event rate 0.6%) treated 
with pioglitazone and 14 cases among 4570 patients (raw 
event rate 0.3%) treated with placebo. Meta- analysis of 
these two trials showed a borderline increase in the risk 
of bladder cancer when pioglitazone was compared with 
placebo (Peto OR, 1.84; 95%CI, 0.99 to 3.42), with no 
evidence of between- study heterogeneity (I2 = 0%; Fig. 2A). 
When excluding the cases diagnosed within the first year 
of exposure to pioglitazone from the PROactive [4, 30], 
a nonsignificantly increased risk of bladder cancer associ-
ated with pioglitazone was observed (Peto OR, 1.63; 95% 
CI, 0.78 to 3.38).
Evidence of observational studies
Twenty studies (12 cohort studies and eight case–control 
studies) involving 4,846,088 individuals reported adjusted 
estimates of bladder cancer [6, 8–11, 31–45] (Table S2). 
Two studies used the same research database (UK General 
Practice Research Database) [31, 39], which might lead 
to overlapping patients. Both studies were included 
because they provided different information and used 
different comparison groups (never- use of pioglitazone 
vs. never- use of thiazolidinedione). Five studies published 
by independent groups were performed in the same 
databases (Taiwan National Health Insurance) [32, 35, 
36, 41, 42]. They were all included as they differed in 
study design, selection of cases and control, and dura-
tion of follow- up, although there may be some overlap-
ping patients. We included one open- label 10- year 
observational follow- up of a RCT (PROactive), which 
was considered a cohort study [10]. Three studies pub-
lished by Lewis et al. used the same database [5, 8, 
46], so we included the longest follow- up study [8] 
and included some data of subgroup from the study 
published in 2011 [5]. The included studies were of 
adequate quality, with more than six stars out of nine 
in the NOS quality assessment (Table S3). Five obser-
vational studies were sponsored by industry (Takeda) 
[8–10, 38, 40].
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Meta- analysis of adjusted estimates from 19 studies that 
provided the data of bladder cancer risk showed that ever 
use of pioglitazone was associated with significantly 
increased risk of bladder cancer compared with never- 
users (OR, 1.13; 95% CI, 1.03 to 1.25), with moderate 
between- study heterogeneity (I2 = 31.3%; Fig. 2B). Our 
cumulative meta- analysis ordered by publication year indi-
cated a significant association between pioglitazone use 
and never users became evident at the end of 2012 (cumu-
lative OR, 1.19; 95% CI, 1.04 to 1.37). The estimates by 
cumulative meta- analysis of subsequent studies resulted 
in a narrow CI (Fig. 3). Our sensitivity analysis by omit-
ting each study successively showed that our results did 
not change evidently even if we excluded the most influ-
ential study by Tuccori et al. [11] (OR, 1.05; 95% CI, 
1.00 to 1.12; Fig. S2). The results also remained stable 
in the additional sensitivity analysis only including the 
study performed by Wei et al. [39] using UK General 
Practice Research Database and the study performed by 
Lee et al. [42] using Taiwan National Health Insurance 
(OR, 1.11; 95% CI, 1.00 to 1.23; Fig. S3). There was no 
evidence of substantial publication bias based on Egger’s 
test (P = 0.09), Begg’s test (P = 0.97), or visual inspec-
tion of the funnel plot (Fig. S4).
The results from stratified analyses are presented in 
Table 1. Our meta- analysis of nine studies that provided 
the stratified results by cumulative duration showed that, 
compared with never- users, pioglitazone use was associated 
with a significantly higher risk of bladder cancer in the 
longest cumulative duration exposure (>2 years: OR, 1.49; 
95% CI, 1.21 to 1.84) and in the moderate cumulative 
duration exposure (1–2 years: OR, 1.25; 95% CI, 1.11 to 
1.40), but not in the shortest cumulative duration exposure 
(≤1 year: OR, 1.07; 95% CI, 0.92 to 1.23). Similarly, the 
meta- analysis of eight observational studies that provided 
the stratified results by cumulative dose showed that ever 
use of pioglitazone was associated with a significantly 
increased risk of bladder cancer in both the highest cumu-
lative dose exposure (>28 g: OR, 1.66; 95% CI, 1.32 to 
2.07) and the moderate cumulative dose exposure (10.5–
28 g: OR, 1.27; 95% CI, 1.05 to 1.54), but not in the 
lowest cumulative dose exposure (<10.5 g: OR, 1.17; 95% 
Figure 1. Flowchart of the identification of eligible studies.
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CI, 0.99 to 1.39). There is some evidence that the increased 
risk of bladder cancer associated with pioglitazone showed 
a time–response relationship (P = 0.01) and dose–response 
relationship (P = 0.04).
The stratified analysis showed that the increased risk 
of bladder cancer varied depending on the populations 
from Europe (OR, 1.17; 95% CI, 1.00 to 1.36), Asia (OR, 
1.11, 95% CI, 0.92 to 1.34), or United States (OR, 1.03; 
95% CI, 0.92 to 1.39), but not significant difference among 
these three groups (P = 0.77). Similarly, there was little 
evidence that the risks differed depending on whether 
pioglitazone compared with never use of any thiazolidin-
edione (OR, 1.62; 95%CI, 1.27 to 2.08), never use of 
pioglitazone (OR, 1.04, 95% CI, 0.99 to 1.09), or other 
comparison groups. An increased risk of bladder cancer 
was observed in the studies with smoking adjusted (OR, 
1.28; 95%CI, 1.02 to 1.61), studies without receiving the 
funding from industry (OR, 1.20; 95%CI, 1.05 to 1.36), 
and cohort studies (OR, 1.21; 95%CI, 1.00 to 1.24). There 
was no significant difference between men and women 
(P = 0.47).
In addition, from seven studies [5, 8, 9, 11, 31, 35, 
42], we found that every 1 year increase in cumulative 
duration was associated with a 5% higher risk of bladder 
cancer (OR, 1.05; 95% CI, 1.02 to 1.09) in the cumula-
tive duration between 0 year and 2 years and every 10 gram 
increase in cumulative dose was associated with a 2% 
higher risk (OR, 1.03; 95% CI, 0.99 to 1.07) in the cumu-
lative dose between 0 g and 30 g. A restricted cubic splines 
model revealed a significant non- linear association between 
cumulative time and risk of bladder cancer (P for non- 
linear trend = 0.003, Fig. 4A). Likewise, cumulative dose 
slightly increased the risk (P for non- linear trend = 0.05, 
Fig. 4B).
Discussion
In this study, we analyzed recent evidence to assess the 
association between pioglitazone and the risk of bladder 
cancer. Our cumulative meta- analysis of evidence from 
observational studies showed that pioglitazone was asso-
ciated with significantly increased risk of bladder cancer 
Figure 2. Meta- analysis of the association between pioglitazone use and risk of bladder cancer based on randomized controlled trials (A) and 
observational studies (B).
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from 2012 onwards and showed borderline increased 
risk when pooling estimate of RCTs. Furthermore, our 
meta- analysis showed that pioglitazone was associated 
with bladder cancer in both time- and dose- response 
manner. The association between increased risk of blad-
der cancer and pioglitazone differed depending on the 
regions and the choices of comparison groups. Moreover, 
the increased risk of bladder cancer was observed in 
the studies which adjusted the smoking status and the 
studies without supporting by industry. Our sensitivity 
analysis indicated that the significant association was 
robust.
Concern persists about the potential risk of bladder 
cancer associated with pioglitazone. Our meta- analysis 
indicated that pioglitazone was associated with a slightly 
but significantly increased risk of bladder cancer, and this 
evidence has been stable since 2012. However, the under-
lying mechanisms have not been fully elucidated. 
Pioglitazone exerts its anti- hyperglycemic effects through 
activation of PPAR γ [1], which is highly expressed not 
only in adipocytes but also in several other tissues (e.g., 
urinary bladder) [47]. Furthermore, PPAR γ is also 
expressed on cancer cells [48]. It has been reported that 
activation of PPAR γ may alter tumor growth and pro-
gression in nonadipose cells [49]. Preclinical research in 
rats showed that high doses of pioglitazone for 2 years 
increased risk of bladder tumors among male rats but 
not among female rats [50]. Recently, one study performed 
on 120 mice showed that prolonged use of pioglitazone 
might induce significant abnormalities in several biomark-
ers and hematological indices associated with histopatho-
logical changes in the bladder, depending on dose [51]. 
In accordance with the findings from animal studies, our 
meta- analysis indicated that greater dose or longer dura-
tion of pioglitazone was associated with higher risk of 
bladder cancer, which supported the notion that piogl-
itazone’s risk of bladder cancer is dose- dependent, in terms 
of cumulative dose or cumulative duration. We also noted 
this risk in the studies with adjusting for the smoking 
status, as smoking is an important risk factor for bladder 
cancer [52]. Furthermore, we found a significantly increased 
risk of bladder cancer in the studies without receiving 
industry funding, which is in contrast to the nulling find-
ings from the studies supported by pharmaceutical company 
(Takeda). Lexchin et al. [53] reported that the studies 
sponsored by pharmaceutical companies were more likely 
to have outcomes favoring the sponsor than were studies 
with other sponsors.
However, it should be noted that 11 cases of bladder 
cancer (eight in pioglitazone group and three in the 
placebo group) from PROactive were diagnosed within 
the first year of treatment [4, 30]. A nonsignificantly 
increased risk of bladder cancer associated with piogl-
itazone was observed when excluding those cases within 
Figure 3. Cumulative meta- analysis of the association between pioglitazone use and risk of bladder cancer based on adjusted data from observational 
studies.
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the first year of exposure. Furthermore, some analyses 
did not suggest a strong dose- dependence relationship. 
Several factors in patients with long duration of diabetes 
might also contribute to the increased risk of bladder 
cancer. In addition, two large observational studies spon-
sored by Takeda did not detect any increased risk of 
bladder cancer among patients with exposure to piogl-
itazone in terms of dose (≤14 g vs. 14–40 g vs. >40 g) 
or duration (≤1.5 years vs. 1.5–4 years vs. >4 years) [8, 
9]. Pioglitazone is generally a second- or third- line oral 
antidiabetic drug, which suggests that patients treated 
with pioglitazone may be elderly, who are more likely 
to have diabetes for a longer time or with higher inci-
dence of comorbidities and complications [54]. These 
factors might lead to the increased risk of bladder cancer 
[55]. Diabetic patients have an increased risk of bladder 
cancer, especially in those with the duration <5 years 
[56]. In addition, the risk of bladder cancer might be 
influenced by the use of other antidiabetic drugs. 
Metformin may prevent, but insulin might promote some 
cancers [57, 58]. Our results indicated that different 
choices of comparison groups might lead to different 
assessments of risk. Gender was also considered as a 
factor that might influence the risk of bladder cancer 
Table 1. Stratified analysis of the association between pioglitazone use and risk of bladder cancer based on adjusted data from observational 
studies.
Number of studies Odds ratio (95%CI) I2 (%) P for heterogeneity
Overall 19 1.13 (1.03, 1.25) 31.3 –
Smoking adjusted
Yes 6 1.28 (1.02, 1.61) 43.1 0.07
No 13 1.03 (0.98, 1.08) 0
Region of study
Europe 8 1.17 (1.00, 1.36) 67.6 0.77
United States 9 1.03 (0.78, 1.36) 0
Asia 2 1.11 (0.92, 1.34) 0
Source of funding
Industry (Takeda) 5 1.00 (0.85, 1.19) 0 0.17
Other 14 1.20 (1.05, 1.36) 43.8
Type of comparators
Never use of Thiazolidinedione 3 1.62 (1.27, 2.08) 0 0.43
Never use of Pioglitazone 13 1.04 (0.99, 1.09) 0
Rosiglitazone 1 1.14 (0.79, 1.65) –
Insulin 1 0.92 (0.63, 1.34) –
Placebo 1 0.65 (0.33, 1.28) –
Design of study
Cohort studies 12 1.12 (1.00, 1.24) 40.1 0.69
Case–control studies 7 1.21 (0.96, 1.56) 7.5
Sex
Men 3 1.12 (0.96, 1.31) 67.3 0.47
Women 3 1.01 (0.98, 1.08) 0
Cumulative dose- 11
≤10.5 g 6 1.17 (0.99, 1.39) 0 0.04
10.5–28 g 4 1.27 (1.05, 1.54) 0
>28 g 4 1.66 (1.32, 2.07) 0
Cumulative dose- 21
≤14 g 2 0.96 (0.79, 1.17) 0 0.80
14–40 g 2 1.07 (0.86, 1.32) 0
>40 g 2 0.92 (0.58, 1.44) 43.5
Cumulative duration- 11
≤1 years 9 1.07 (0.92, 1.23) 33.9 0.01
1–2 years 7 1.25 (1.11, 1.40) 0.2
>2 years 7 1.49 (1.21, 1.84) 57.5
Cumulative duration- 21
≤1.5 years 2 0.97 (0.78, 2.82) 0 0.53
1.5–4 years 2 0.94 (0.73, 1.22) 20.5
>4 years 2 1.11 (0.85, 1.44) 0
1Some studies provide the results by cumulative dose (≤10.5 g vs. 10.5–28 g vs. >28 g;) or cumulative duration (≤1 year vs. 1–2 years vs. >2 years), 
while other studies provide the data based on cumulative dose (≤1.5 year vs. 1.5–4 years vs. >4 years) or cumulative duration (≤14 g vs. 14–40 g vs. 
>40 g).
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[56, 59]. One cohort study performed in France showed 
a significant association between pioglitazone and bladder 
cancer among men but not in women [6]. However, 
our meta- analysis did not indicate significant gender 
difference. These factors require further investigation.
Interestingly, our results indicate that the increased risk 
of bladder cancer associated with pioglitazone was detected 
in European populations, but not in US or Asian popula-
tions. Differences among ethnicities might be involved. 
A higher rate of bladder cancer was observed in Caucasians 
when compared with Blacks and Asians [60]. European 
populations primarily consist of white subjects, while those 
from Asia of course consist of Asian patients. In the 
United States, the race among different ethnicities differs 
markedly, with Caucasians having the highest rate. The 
differences in risk of bladder cancer among these popula-
tions could be explained by dissimilar genetic backgrounds, 
or possibly by the dietary, socioeconomic, and cultural 
differences among ethnicities [52].
Six meta- analyses were conducted to evaluate the asso-
ciation between pioglitazone and risk of bladder cancer 
(Table S4) [13–18]. These meta- analyses were published 
between 2012 and 2014 with the latest search time in 
July 2013. All found that pioglitazone was associated with 
significantly increased risk of bladder cancer, of which 
two detected a dose- response relationship and others 
identified a duration- response relationship. Compared with 
these studies, our meta- analysis has data updated as of 
August 2016 and included two large randomized trials 
and 20 observational studies, of which one large trial and 
several large observational studies were published since 
July 2013. We provide more substantial evidence of an 
association between increased risk of bladder cancer and 
pioglitazone use in European populations and suggest the 
choices of comparison groups might influence the results. 
Our findings also indicated some evidence of bias induced 
by pharmaceutical companies. In addition, our cumulative 
and sensitivity meta- analysis indicated that the positive 
association was robust.
Our study has several strengths. First, we systematically 
searched electronic databases and included both rand-
omized trials and observational studies to evaluate the 
association between pioglitazone and risk of bladder cancer. 
Second, we explored sources of heterogeneity by perform-
ing meta- regression meta- analysis and several prespecified 
stratified analyses. Third, we assessed the robustness of 
evidence by carrying out cumulative and sensitivity analyses. 
Finally, a restricted spline regression analysis was used to 
examine the dose- response relationship with a generalized 
least- squares trend test. We also acknowledge that our 
meta- analysis has several limitations. First, our results 
should be interpreted with caution due to between- study 
heterogeneity in exposure and population. The duration 
of follow- up, duration of diabetes, and other drugs used 
varied across studies, although several prespecified strati-
fied analyses were performed to minimize the heterogeneity. 
The cumulative dose and cumulative duration of piogl-
itazone use were different. Furthermore, not every study 
included these results for inclusion in our meta- analysis. 
Second, different observational studies adjusted for dif-
ferent sets of confounders, although we used the risk 
estimates that fully adjusted for the covariates and per-
formed a stratified analysis by major factor adjusted 
(smoking status). Third, several studies performed a nested 
case–control in a cohort and reported both results [8, 
40]. We just used the results from the cohort. Finally, 
rosiglitazone was not assessed in our study because of 
current studies and meta- analyses have found no associa-
tion between its use and bladder cancer [11, 14].
In summary, our meta- analysis of currently available 
evidence suggests that pioglitazone is associated with slightly 
but significantly increased risk of bladder cancer, 
Figure 4. Dose–response relationship between cumulative duration (A) 
and cumulative dose (B) and risk of bladder cancer in a restricted cubic 
spline random- effects meta- analysis based on adjusted data from 
observational studies. Note: The solid lines and the long dash lines 
represent the estimated odds ratios and their corresponding 95% 
confidence intervals of non- linear model, respectively. The short dash 
lines represent estimated odds ratios of linear model.
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indicating a time- and dose- response relationship. The 
risk of bladder cancer associated with pioglitazone is vari-
ous and depended on ethnicity and choice of comparison 
group. Our updated and detailed information suggests 
cautions and closely monitoring signs for bladder cancer 
in patients with T2DM, who use pioglitazone, especially 
those requiring higher doses and longer duration of treat-
ment. However, further well- designed and well- conducted 
studies that clearly define study population and exposure, 
and adequately adjust confounders are needed to confirm 
our findings.
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